Metabolic consequences of reduced gastric acidity

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Antacids, anticholinergics, and histamine H2-antagonists are commonly used to reduce stomach acidity.
• Long-term antacid use is associated with significant metabolic complications like milk-alkali syndrome and phosphorus depletion.
• The metabolic effects of anticholinergics and H2-antagonists require further investigation.

Purpose of the Study:

• To review the metabolic effects of antacids, anticholinergics, and histamine H2-antagonists.
• To investigate the long-term metabolic consequences of continuous cimetidine treatment.

Main Methods:

• Literature review on antacids, anticholinergics, and H2-antagonists.
• Clinical study involving continuous cimetidine (400 mg) administration for three years.
• Monitoring of weight, hemoglobin, plasma iron, folate, vitamin B12, albumin, and calcium levels.

Main Results:

• Antacids can cause severe metabolic complications, including phosphorus depletion and milk-alkali syndrome.
• Continuous cimetidine treatment for three years resulted in only a slight, non-significant decrease in plasma calcium within normal ranges.
• Anticholinergics have minimal known metabolic effects, with no serious consequences indicated by clinical experience.

Conclusions:

• Moderate, intermittent acid reduction with anticholinergics or standard H2-antagonist doses is unlikely to cause metabolic issues.
• Higher doses or more frequent administration of H2-antagonists may increase the risk of bacterial overgrowth and subsequent metabolic consequences.
• Careful consideration of dosage and frequency is necessary to mitigate potential metabolic risks associated with acid-reducing medications.